Anxiety and depression are often overlooked and underdiagnosed both in patients as well as in family members and caregivers of pre-school children. AD is a considerable burden, also for family members. In addition, the clinical spectrum of AD often includes insomnia, which can also affect the parents of small kids.
To evaluate the psychosocial effect of AD on their family members and caregivers, researchers from the Phi University Clinic of Dermatology in Skopje sent out a 7-item questionnaire in which they asked about the greatest worries of caregivers. It also contained a Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating scale (HAM-A) for evaluation of the symptoms of depression and anxiety of family members and caregivers of 35 patients with AD aged 1 to 6. The severity of AD was scored using the Scoring of Atopic Dermatitis (SCORAD).
A total of 83 family members and caregivers were evaluated. All questionnaire respondents reported at least mild-severity anxiety with some showing moderate-severity anxiety. The average score on the HAM-A scale was 12.9 ± 4.8. In addition, almost 3 in 4 (74%) participants were also found to suffer from depression. Interestingly, the highest HAM-A and HAM-D score were not associated with the highest SCORAD values, but with persistence and longevity of AD. The most frequent worry reported by the families was the information families and caregivers received about the nature of the disease itself, since AD is a long-term condition which requires complex and costly medical treatments.
Dr Vesna Grivcheva-Panovska said: âThe chronicity and complexity of chronic dermatitis often leads to overlooked anxiety and depression in family members and caregivers and our results show that the extent of this cannot be overstated. In the future, we must take a wholesome view of the situation and a widened approach to the management of AD, not only for the patients but for their families as well.â Keeping this in mind, dermatologists should actively look for symptoms of depression or anxiety in families with AD, and, if necessary, refer affected persons to specialists.
- Grivcheva-Panovska V, et al. P0273, EADV 2019, 9-13 Oct, Madrid, Spain.
Posted on
Previous Article
« D-Dimer as future biomarker in CSU management? Next Article
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker »
« D-Dimer as future biomarker in CSU management? Next Article
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker »
Table of Contents: EADV 2019
Featured articles
Late-Breaking News
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Emerging Therapies
Small molecules: interesting novel treatment options in AD
IL-1âș blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Urticaria
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea â From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Related Articles
September 17, 2021
Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis
December 9, 2019
Biologics: increasingly used in paediatric dermatology
December 17, 2020
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com